Evidence map›Paper›PMID 35151251›Full record

ArticleBMC neurology2022

Whole-exome sequencing confirms implication of VPS13D as a potential cause of progressive spastic ataxia.

Christelle M Durand, Chloé Angelini, Vincent Michaud, Claire Delleci, Isabelle Coupry, Cyril Goizet, Aurelien Trimouille

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. An optimized temporally controlled Gal4 system inFrontiers in neuroscience · 2023
    Article
  7. Vps13 is required for efficient autophagy inContact (Thousand Oaks (Ventura County, Calif.))
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Christelle M DurandINSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux Univ., CHU Bordeaux - Hôpital Pellegrin - Place Amélie Raba Léon, 33076, Bordeaux Cedex, France. christelle.durand@u-bordeaux.fr.ORCID http://orcid.org/0000-0002-3890-0632
Chloé AngeliniCentre de Référence Neurogénétique, Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.
Vincent MichaudINSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux Univ., CHU Bordeaux - Hôpital Pellegrin - Place Amélie Raba Léon, 33076, Bordeaux Cedex, France.
Claire DelleciCentre de Référence Neurogénétique, Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.
Isabelle CoupryINSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux Univ., CHU Bordeaux - Hôpital Pellegrin - Place Amélie Raba Léon, 33076, Bordeaux Cedex, France.
Cyril GoizetINSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux Univ., CHU Bordeaux - Hôpital Pellegrin - Place Amélie Raba Léon, 33076, Bordeaux Cedex, France.
Aurelien TrimouilleINSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux Univ., CHU Bordeaux - Hôpital Pellegrin - Place Amélie Raba Léon, 33076, Bordeaux Cedex, France.
Inserm · FRHôpital Pellegrin · FRUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVPS13D is a large ubiquitin-binding protein playing an essential role in mitophagy by regulating mitochondrial fission. Recently, VPS13D biallelic pathogenic variants have been reported in patients displaying variable neurological phenotypes, with an autosomic recessive inheritance. The objectives of the study were to determine the genetic etiology of a patient with early onset sporadic progressive spastic ataxia, and to investigate the pathogenicity of VPS13D variants through functional studies on patient's skin fibroblasts. CASE PRESENTATION: We report the case of a 51-year-old patient with spastic ataxia, with an acute onset of the disease at age 7. Walking difficulties slowly worsened over time, with the use of a wheelchair since age 26. We have used trio-based whole-exome sequencing (WES) to identify genes associated with spastic ataxia. The impact of the identified variants on mitochondrial function was assessed in patient's fibroblasts by imaging mitochondrial network and measuring level of individual OXPHOS complex subunits. Compound heterozygous variants were identified in VPS13D: c.946C > T, p.Arg316* and c.12416C > T, p.(Ala4139Val). Primary fibroblasts obtained from this patient revealed an altered mitochondrial morphology, and a decrease in levels of proteins from complex I, III and IV.

conclusionsOur findings confirmed implication of VPS13D in spastic ataxia and provided further support for mitochondrial defects in patient's skin fibroblasts with VPS13D variants. This report of long-term follow up showed a slowly progressive course of the spastic paraplegia with cerebellar features. Furthermore, the performed functional studies could be used as biomarker helping diagnosis of VPS13D-related neurological disorders when molecular results are uneasy to interpret.

Indexed as

Optic AtrophySpastic Paraplegia, HereditarySpinocerebellar AtaxiasAdultChildExome SequencingHumansIntellectual DisabilityMiddle AgedMuscle SpasticityMutationPedigreePhenotypeProteinsProteinsVPS13D protein, humanMitochondrial networkSpastic ataxiaVPS13DWhole exome sequencing

Identifiers

PMID35151251
PMCPMC8840315
OpenAlexW4211030912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.